Clinical Trial Highlights

• No Benefit from BP-Lowering in Acute Stroke
• No Added Benefit from EC-IC Bypass Surgery When Added to Standard Medical Therapy in Preventing Recurrence of Ipsilateral Stroke
• Fluoxetine Improves Motor Function in Patients with Severe Motor Deficit When Given Early after Ischemic Stroke
• No Significant Improvement in Vasospasm-Related Morbidity or All-Cause Mortality with Clazosentan after aSAH
• Severity of Deficit Strongly Predicts Long-Term Survival among Stroke Survivors
• Apixaban Associated with Reduction in Stroke and SE in Patients Unsuitable for VKA Therapy
• No Advantage for Percutaneous Closure of PFO versus Medical Therapy in Reducing Recurrent Neurological Events
• Results from the LEAPS Trial
• Combination Full-Dose IV-tPA + Argatroban is Safe and May Result in Higher Rates of Recanalization
• Results from the SENTIS Trial